CN110248662A - 一种治疗***癌的组合、药物组合物及治疗方法 - Google Patents

一种治疗***癌的组合、药物组合物及治疗方法 Download PDF

Info

Publication number
CN110248662A
CN110248662A CN201780085859.9A CN201780085859A CN110248662A CN 110248662 A CN110248662 A CN 110248662A CN 201780085859 A CN201780085859 A CN 201780085859A CN 110248662 A CN110248662 A CN 110248662A
Authority
CN
China
Prior art keywords
combination
prednisone
abiraterone
galeterone
odm201
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780085859.9A
Other languages
English (en)
Other versions
CN110248662B (zh
Inventor
戈传生
廖柏松
李文成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kangpu Biopharmaceutical Technology Hefei Co ltd
Original Assignee
Kangpu Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangpu Biopharmaceuticals Ltd filed Critical Kangpu Biopharmaceuticals Ltd
Publication of CN110248662A publication Critical patent/CN110248662A/zh
Application granted granted Critical
Publication of CN110248662B publication Critical patent/CN110248662B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一种治疗***癌的组合、药物组合物及治疗方法。本发明公开的组合包含通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，以及雄激素受体通路调节剂。本发明的组合、其药物组合物及治疗方法能够更有效地抑制***癌。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780085859.9A 2017-02-13 2017-02-13 一种治疗***癌的组合、药物组合物及治疗方法 Active CN110248662B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/073380 WO2017067530A2 (zh) 2017-02-13 2017-02-13 一种治疗***癌的组合、药物组合物及治疗方法

Publications (2)

Publication Number Publication Date
CN110248662A true CN110248662A (zh) 2019-09-17
CN110248662B CN110248662B (zh) 2022-08-16

Family

ID=58558089

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780085859.9A Active CN110248662B (zh) 2017-02-13 2017-02-13 一种治疗***癌的组合、药物组合物及治疗方法

Country Status (12)

Country Link
US (3) US20200000776A1 (zh)
EP (1) EP3581182B1 (zh)
JP (1) JP6773915B2 (zh)
KR (1) KR102125661B1 (zh)
CN (1) CN110248662B (zh)
AU (1) AU2017202864B2 (zh)
CA (1) CA3053805C (zh)
ES (1) ES2899372T3 (zh)
PL (1) PL3581182T3 (zh)
RU (1) RU2733950C1 (zh)
WO (1) WO2017067530A2 (zh)
ZA (1) ZA201905222B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
PT3527210T (pt) 2016-12-16 2021-08-11 Kangpu Biopharmaceuticals Ltd Composição combinada que compreende um composto benzo-heterocíclico e um modulador da via dos recetores de androgénio e usos da mesma
KR102014478B1 (ko) 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2019032840A1 (en) * 2017-08-09 2019-02-14 Druggability Technologies Ip Holdco Limited PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DAROLUTAMIDE
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
KR20210016515A (ko) * 2018-03-29 2021-02-16 하이노바 파마슈티컬스 인코포레이티드 중수소화 이미다졸리딘디온 화합물 및 이의 용도
HUE064340T2 (hu) 2018-04-23 2024-03-28 Celgene Corp Szubsztituált 4-aminoizoindolin-1,3-dion-származékok és alkalmazásuk limfóma kezelésére
EP3795153A4 (en) * 2018-05-14 2022-03-09 Hinova Pharmaceuticals Inc. FORMULATION BASED ON HC-1119, METHOD FOR PREPARATION AND USE THEREOF
CN111514140B (zh) * 2019-02-01 2021-09-03 江苏恒瑞医药股份有限公司 一种mek抑制剂联合雄激素受体拮抗剂在制备***药物中的用途
AU2020272978A1 (en) 2019-04-12 2021-09-16 C4 Therapeutics, Inc. Tricyclic degraders of Ikaros and Aiolos
KR102479869B1 (ko) 2020-06-05 2022-12-21 중앙대학교 산학협력단 당단풍나무 추출물 또는 이의 분획물을 포함하는 전립선암 예방, 치료, 또는 개선용 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1720045A (zh) * 2002-11-06 2006-01-11 细胞基因公司 包含免疫调节化合物的组合物及使用该组合物治疗和控制骨髓增生性疾病的方法
US20080119443A1 (en) * 2006-07-03 2008-05-22 Academia Sinica Certain lithocholic acid analogues that inhibit sialyltransferase
CN102482230A (zh) * 2009-09-10 2012-05-30 童友之 雄激素受体拮抗剂及其用途
CN103608333A (zh) * 2011-03-10 2014-02-26 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
CN103958480A (zh) * 2012-09-04 2014-07-30 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
CN104211683A (zh) * 2013-05-29 2014-12-17 成都海创药业有限公司 咪唑二酮类化合物及其用途
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
CN105566290A (zh) * 2014-10-30 2016-05-11 康朴生物医药技术（上海）有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333903A (en) 1996-07-24 2000-02-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ME01421B (me) 2006-09-26 2013-12-20 Celgene Corp 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
DK3202461T3 (en) * 2010-02-11 2019-03-18 Celgene Corp ARYLMETHOXY-ISOINDOLIN DERIVATIVES AND COMPOSITIONS COMPREHENSIVE AND PROCEDURE FOR USE THEREOF
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
EP2911666B1 (en) * 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
AU2014236597A1 (en) * 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
AU2015247817C1 (en) * 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
CN106551934B (zh) * 2015-09-29 2020-09-11 康朴生物医药技术（上海）有限公司 一种药物组合物及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1720045A (zh) * 2002-11-06 2006-01-11 细胞基因公司 包含免疫调节化合物的组合物及使用该组合物治疗和控制骨髓增生性疾病的方法
JP2011079851A (ja) * 2002-11-06 2011-04-21 Celgene Corp 骨髄増殖性疾患の治療および管理のための免疫調節化合物を含む使用方法および組成物
US20080119443A1 (en) * 2006-07-03 2008-05-22 Academia Sinica Certain lithocholic acid analogues that inhibit sialyltransferase
CN102482230A (zh) * 2009-09-10 2012-05-30 童友之 雄激素受体拮抗剂及其用途
CN103608333A (zh) * 2011-03-10 2014-02-26 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
CN103958480A (zh) * 2012-09-04 2014-07-30 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
CN104211683A (zh) * 2013-05-29 2014-12-17 成都海创药业有限公司 咪唑二酮类化合物及其用途
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
CN105566290A (zh) * 2014-10-30 2016-05-11 康朴生物医药技术（上海）有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘琪 等: "转移性去势抵抗性***癌药物治疗进展", 《现代泌尿外科杂志》 *

Also Published As

Publication number Publication date
ZA201905222B (en) 2020-05-27
US20240139156A1 (en) 2024-05-02
WO2017067530A3 (zh) 2017-12-21
JP2020506216A (ja) 2020-02-27
KR102125661B1 (ko) 2020-06-22
JP6773915B2 (ja) 2020-10-21
CA3053805A1 (en) 2017-04-27
CA3053805C (en) 2020-06-30
EP3581182A2 (en) 2019-12-18
US20200000776A1 (en) 2020-01-02
KR20190111133A (ko) 2019-10-01
NZ756412A (en) 2021-01-29
AU2017202864B2 (en) 2020-04-23
WO2017067530A2 (zh) 2017-04-27
AU2017202864A1 (en) 2019-09-26
RU2733950C1 (ru) 2020-10-08
ES2899372T3 (es) 2022-03-11
US20210267946A1 (en) 2021-09-02
PL3581182T3 (pl) 2022-01-17
EP3581182A4 (en) 2020-02-26
EP3581182B1 (en) 2021-09-29
CN110248662B (zh) 2022-08-16

Similar Documents

Publication Publication Date Title
CN110248662A (zh) 一种治疗***癌的组合、药物组合物及治疗方法
RU2705576C2 (ru) Фармацевтическая композиция для предупреждения и/или лечения рака предстательной железы, применение бензогетероциклического соединения и способ предупреждения и/или лечения рака предстательной железы
CN110382483A (zh) 稠合的n-杂环化合物及其使用方法
CN110382482A (zh) 稠合的杂-杂二环化合物及其使用方法
CN110036010A (zh) Kras g12c突变蛋白的抑制剂
CN106687139A (zh) 用于治疗癌症的组合
CA3188171A1 (en) Compositions and methods for treating diseases and disorders
CN110049765A (zh) 一种组合、其应用及治疗方法
WO2023220227A1 (en) Treating diseases and disorders with irak4-modifying compounds
WO2020165646A1 (en) Crystalline forms of an rsk inhibitor
JP6629753B2 (ja) がん治療剤の組合せ
NZ756412B2 (en) Combination treating prostate cancer, pharmaceutical composition and treatment method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007591

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Room 401, 4th Floor, Building B1, Block B, Yungu Innovation Park, No. 868 Sichuan Road, Baohe District, Hefei City, Anhui Province, 230022

Patentee after: Kangpu Biopharmaceutical Technology (Hefei) Co.,Ltd.

Country or region after: China

Address before: Room 818, 780 Cailun Road, Zhangjiang High-tech Park, Pudong New Area, Shanghai, 201203

Patentee before: KANGPU BIOPHARMACEUTICALS, Ltd.

Country or region before: China